- In October 2024, Aero Pump and Resyca announced a partnership to launch the innovative Ultra Soft Nasal Pump Spray. The Ultra Soft Nasal Pump Spray was meant for nose-to-brain therapies and provides an innovative non-invasive approach to drug delivery to the central nervous system via the nasal cavity. This launch greatly enhanced the company's market presence
- In October 2024, Aptar Pharma, a leader in drug delivery systems, announced the acquisition of all active technology from the proprietary portfolio of SipNose nasal delivery systems, a company manufacturing specialized systems for intranasal delivery of local, systemic, and central nervous system (CNS) drugs. This acquisition strengthened the company's portfolio, broadened its reach, and optimized patient treatment solutions through enhanced nasal drug devices
- In January 2024, Recipharm signed into a License & Collaboration Agreement with Medspray and Resyca, aimed at developing nasally-delivered drug products utilizing proprietary soft mist technology
- In August 2023, Tiziana Life Sciences announced the FDA clearance of intranasal Foralumab for the treatment of patients suffering from Alzheimer's disease
- In June 2023, the FDA announced the extension of its review period of the New Drug Application (NDA) for neffy (intranasal (IN) epinephrine) for the treatment of severe allergic reactions.
- In June 2023, Seelos Therapeutics announced the closure of enrollment of its registration directed study focusing on SLS-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior in adults suffering from major depressive disorder
